Shares of Great Basin Scientific Inc (NASDAQ:GBSN) ended Thursday session in green amid volatile trading. The shares closed up +0.05 points or 1.34% at $3.78 with 2.13 million shares getting traded. Post opening the session at $4.95, the shares hit an intraday low of $3.57 and an intraday high of $5.48 and the price vacillated in this range throughout the day. The company has a market cap of $2.87 million and the numbers of outstanding shares have been calculated to be 803,437.00 shares.
Great Basin Scientific Inc (GBSN) on Sept. 20, 2016 announced the U.S. and European commercial launch of its Staph ID/R Blood Culture Panel, the Company’s first multiplex panel. This sample-to-result, automated panel benefits hospitals and laboratories by detecting, in about two hours, bloodstream infections caused by MRSA and other Staphylococcus species, enabling accurate, timely, and cost-effective diagnosis and treatment of patients. The panel detects the mecA gene, a major drug resistance marker that confers resistance to methicillin and other beta-lactams and creates the superbug MRSA. The assay is unique in its ability to distinguish Coagulase-negative Staphylococci (CoNS), which may not require treatment with antibiotics, from pathogenic Staphylococci, and can therefore assist healthcare organizations with antimicrobial stewardship programs and campaigns.
“The commercial launch of our Staph ID/R Blood Culture Panel marks a major milestone in our growth as a company as we deliver on our unique capability of providing low-plex, direct-from-specimen and multiplex testing on a single platform,” said Ryan Ashton, co-founder and chief executive officer of Great Basin Scientific. “Additionally, we’re pleased to be able to offer a significant tool for hospitals and labs as they implement antimicrobial stewardship programs into their broader healthcare strategy. The need for a solution to help clinicians battle antibiotic resistance is so great, nearly half of our installed customer base has already expressed an interest in our Staph ID/R Blood Culture Panel. Further, this panel is opening doors for our sales team at new larger sites not previously open to the Great Basin platform. Our Staph ID/R Blood Culture Panel will allow the clinical laboratory to play an important role in achieving the antimicrobial stewardship goals of improving patient care, reducing costs, and combating emerging antimicrobial resistance.”
Shares of Pfizer Inc. (NYSE:PFE) ended Thursday session in green amid volatile trading. The shares closed up +0.16 points or 0.48% at $33.81 with 14.11 million shares getting traded. Post opening the session at $33.84, the shares hit an intraday low of $33.60 and an intraday high of $33.94 and the price vacillated in this range throughout the day. The company has a market cap of $203.33 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. (PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2016 Performance Report, to be issued that morning.
To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Quarterly Corporate Performance – Third Quarter 2016” link in the For Investors section located on the lower right-hand corner of that page. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning now. Participants are advised to pre-register in advance of the conference call.
You can also listen to the conference call by dialing either (866) 662-3198 in the United States and Canada or (484) 747-6805 outside of the United States and Canada. The password is “Third Quarter Earnings”.